Skip to main content
. 2021 Jun 24;16(6):e0251646. doi: 10.1371/journal.pone.0251646

Fig 3.

Fig 3

Microscopic image of the pancreas of (A) untreated rats (N, control group), (B) streptozotocin (STZ)-treated rats (DM, STZ group), and (C–E) STZ + ProbiogluTM-treated rats (DM1X: STZ + 1× ProbiogluTM group, 5.17 × 109 CFU kg-1 d-1; DM5X: STZ + 5× ProbiogluTM group, 2.58 × 1010 CFU kg-1 d-1; DM10X: STZ + 10× ProbiogluTM group, 5.17 × 1010 CFU kg-1 d-1) at the end of the experimental period. (F) Mean β-cell mass in each group at the end of the experimental period. Each group consisted of 8 rats in this study. * indicates significant differences compared with the control: p < 0.05.